Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE The biggest advances have been made with CAR T cells and many of those studies are now FDA approved as a routine treatment for some hematologic malignancies. 31705854 2020
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Recently, the use of chimeric antigen receptor modified T (CAR-T)-cells in the treatment of hematological tumors has been successful and has become a clinical hotspot in tumor immunotherapy. 31790761 2020
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE CAR-T cell-based immunotherapy has shown great promise in clinical trials for the treatment of hematological malignancies. 31814915 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 GeneticVariation group BEFREE This study offers a reference for future research regarding the application in solid and hematologic malignancies, side effects and relapse, and even the production processes of CAR T cells. 30621018 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies. 31186046 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE It is therefore hypothesized that targeting CAR T cells towards the tumor vasculature of solid tumors may share the excellent effects of CAR T cell therapy with that against hematological malignancies. 31628559 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Despite the great success of chimeric antigen receptor T (CAR-T)-cell therapy in the treatment of hematologic malignancies, CAR-T-cell therapy is limited in solid tumors, including hepatocellular carcinoma (HCC). 31484657 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE This review focuses on application of CAR-T cells in hematologic malignancies beyond targeting CD19, with specific attention to Hodgkin's lymphoma and acute myeloid leukemia. 30632631 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy that is widely used to treat hematological malignancies, including acute leukemia, lymphoma, and multiple myeloma. 31571160 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE <b>Aim:</b> Chimeric antigen receptor-engineered T (CAR-T) cells have gained huge success in treating hematological malignancies, yet the CD3ζ-based CAR-T therapies have not shown comparable clinical benefits in solid tumors. 31268375 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Despite its revolutionary success in hematological malignancies, chimeric antigen receptor T (CAR-T) cell therapy faces disappointing clinical results in solid tumors. 30734529 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown exhilarative clinical efficacy for hematological malignancies. 31754328 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Chimeric Antigen Receptor-T (CAR-T) cell immunotherapy has produced dramatic responses in hematologic malignancies. 30760795 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Clinical success of autologous CD19-directed chimeric antigen receptor T cells (CAR Ts) in acute lymphoblastic leukemia and non-Hodgkin lymphoma suggests that CAR Ts may be a promising therapy for hematological malignancies, including multiple myeloma. 31005597 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Chimeric antigen receptor-engineered T (CAR-T)-cell therapy holds significant promise for the treatment of hematological malignancies, especially for B-cell leukemia and lymphoma. 31432594 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Therefore, the inhospitable solid TME becomes a major hurdle in translating the success of CAR T cell therapy in hematological malignancies to solid tumors. 30906625 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE CAR-T has shown promise in a number of other hematologic malignancies, and toxicities have become more manageable as its use is becoming more widespread. 30715612 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Although CAR T cell therapy mediates robust responses in patients with hematological malignancies, this approach has been less effective for treating patients with solid tumors. 30842774 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma. 30841880 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Innovative approaches such as haploidentical stem cell transplantation, new monoclonal antibodies and immunotherapies as well as Chimeric Antigen Receptor T-cell (CAR-T cell) therapies are on the way as promising treatment options especially for patients with refractory hematologic malignancies and even in solid tumors. 29556955 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Currently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughs in the treatment of hematological malignancies, including relapsed or refractory lymphoblastic leukemia and refractory large B-cell lymphoma. 30659408 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Chimeric antigen receptor-modified T (CAR-T) cells have achieved significant success in the treatment of several hematological malignancies. 31221182 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Although CAR T-cell therapy has demonstrated tremendous clinical efficacy especially in hematological malignancies, severe treatment-associated toxicities still compromise the widespread application of this innovative technology. 31414180 2019
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 GeneticVariation group BEFREE CAR-T therapy has shown great success treating blood cancers, but drawbacks include high manufacturing costs and potentially fatal toxicities such as cytokine release syndrome. 30075127 2018
Entrez Id: 653108
Gene Symbol: CXADRP1
CXADRP1
0.100 Biomarker group BEFREE Because CAR-T therapy has shown great success in treating CD19-positive hematological malignancies, its application has been explored in the treatment of solid tumors, such as liver cancer. 29861325 2018